Dapagliflozin reduces pulmonary vascular damage and susceptibility to atrial fibrillation in right heart disease-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Dapagliflozin reduces pulmonary vascular damage and susceptibility to atrial fibrillation in right heart disease

Published:2022-11-11 Issue:1 Volume:10 Page:578-593
ISSN:2055-5822
Container-title:ESC Heart Failure
language:en
Short-container-title:ESC Heart Failure

Author:

Dai Chang¹²³,Kong Bin¹²³,Shuai Wei¹²³,Xiao Zheng¹²³,Qin Tianyou¹²³,Fang Jin¹²³,Gong Yang¹²³,Zhu Jun¹²³,Liu Qi¹²³,Fu Hui¹²³,Meng Hong¹²³,Huang He¹²³

Affiliation:

1. Department of Cardiology Renmin Hospital of Wuhan University 238 Jiefang Road 430060 Wuhan Hubei P.R. China

2. Cardiovascular Research Institute of Wuhan University Wuhan Hubei P.R. China

3. Hubei Key Laboratory of Cardiology Wuhan Hubei P.R. China

Funder

Fundamental Research Funds for the Central Universities

National Natural Science Foundation of China

Publisher

Wiley

Subject

Cardiology and Cardiovascular Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/ehf2.14169

Reference56 articles.

1. SGLT2 inhibitors: the statins of the 21st century

2. The Dapagliflozin And Prevention of Adverse‐outcomes in Heart Failure (DAPA‐HF) trial: baseline characteristics

3. Efficacy and Safety of Dapagliflozin in Heart Failure With Reduced Ejection Fraction According to Age

4. Effects of Dapagliflozin on Symptoms, Function, and Quality of Life in Patients With Heart Failure and Reduced Ejection Fraction

5. Efficacy of Dapagliflozin on Renal Function and Outcomes in Patients With Heart Failure With Reduced Ejection Fraction

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cardioprotection of Canagliflozin, Dapagliflozin, and Empagliflozin: Lessons from preclinical studies;Chemico-Biological Interactions;2024-11

2. Atrial Arrhythmias in Patients With Pulmonary Hypertension;CHEST;2024-07

3. SGLT2 inhibitors as a potential therapeutic option for pulmonary hypertension: mechanisms and clinical perspectives;Critical Reviews in Clinical Laboratory Sciences;2024-06-07

4. Emerging therapies: Potential roles of SGLT2 inhibitors in the management of pulmonary hypertension;Respiratory Medicine;2024-06

5. Management of Pulmonary Hypertension in the Context of Heart Failure with Preserved Ejection Fraction;Current Hypertension Reports;2024-04-01

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3